1. Non-alcoholic fatty liver disease: An early mediator predicting metabolic syndrome in obese children?
- Author
-
Chun-Lin Wang, Xiyong Liu, Ping Jiang, Li-Rui Liu, Hong-bo Shi, Junfen Fu, and Li Liang
- Subjects
Male ,medicine.medical_specialty ,Adolescent ,Letters To The Editor ,Liver disease ,Insulin resistance ,Non-alcoholic Fatty Liver Disease ,Internal medicine ,medicine ,Humans ,Obesity ,Child ,Ultrasonography ,Metabolic Syndrome ,business.industry ,Metabolic disorder ,Fatty liver ,Gastroenterology ,nutritional and metabolic diseases ,General Medicine ,Glucose Tolerance Test ,medicine.disease ,Impaired fasting glucose ,digestive system diseases ,Fatty Liver ,Endocrinology ,Liver ,Elevated transaminases ,Female ,Metabolic syndrome ,Insulin Resistance ,business ,Dyslipidemia - Abstract
AIM: To investigate if non-alcoholic fatty liver disease (NAFLD) is an early mediator for prediction of metabolic syndrome, and if liver B-ultrasound can be used for its diagnosis. METHODS: We classified 861 obese children (6-16 years old) into three subgroups: group 0 (normal liver in ultrasound and normal transaminases); group 1 (fatty liver in ultrasound and normal transaminases); and group 2 (fatty liver in ultrasound and elevated transaminases). We measured the body mass index, waist and hip circumference, blood pressure, fasting blood glucose, insulin, homeostasis model assessment of insulin resistance (HOMA-IR), whole-body insulin sensitivity index (WBISI), lipid profile and transaminases in all the participants. The risk of developing metabolic syndrome (MS) was assessed according to the degree of liver fatty infiltration based on the B-ultrasound examination. RESULTS: Among the 861 obese children, 587 (68.18%) were classified as having NAFLD, and 221 (25.67%) as having MS. The prevalence of MS in NAFLD children (groups 1 and 2) was 37.64% (221/587), which was much higher than that in non-NAFLD group (group 0, 12.04%) (P < 0.01). There were significantly higher incidences concerning every component of MS in group 2 compared with group 0 (P < 0.05). The incidence of NAFLD in MS patients was 84.61% (187/221), which was significantly higher than that of hypertension (57.46%, 127/221) and glucose metabolic anomalies (22.62%, 50/221), and almost equal to the prevalence of dyslipidemia (89.14%, 197/221). Based on the B-ultrasound scales, the presence of moderate and severe liver fatty infiltration carried a high risk of hypertension [odds ratio (OR): 2.18, 95% confidence interval (95% CI): 1.27-3.75], dyslipidemia (OR: 7.99, 95% CI: 4.34-14.73), impaired fasting glucose (OR: 3.65, 95% CI: 1.04-12.85), and whole MS (OR: 3.77; 95% CI: 1.90-7.47, P < 0.01). The state of insulin resistance (calculated by HOMA-IR and WBISI) deteriorated as the degree of fatty infiltration increased. CONCLUSION: NAFLD is not only a liver disease, but also an early mediator that reflects metabolic disorder, and liver B-ultrasound can be a useful tool for MS screening.
- Published
- 2010